Home » Stocks » MLND

Millendo Therapeutics, Inc. (MLND)

Stock Price: $1.94 USD 0.06 (3.19%)
Updated Jan 22, 2021 1:36 PM EST - Market open
Market Cap 33.83M
Revenue (ttm) n/a
Net Income (ttm) -41.74M
Shares Out 19.00M
EPS (ttm) -2.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $1.94
Previous Close $1.88
Change ($) 0.06
Change (%) 3.19%
Day's Open 1.88
Day's Range 1.88 - 1.95
Day's Volume 289,723
52-Week Range 1.40 - 9.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 weeks ago

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces updates on its pipeline and business, including its Phase 1 study of MLE-301 for the treatment of vasomotor symptoms.

Business Wire - 2 months ago

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces operating and financial results for the quarter ended September 30, 2020.

GuruFocus - 3 months ago

There are some investors who buy stocks that are trading below their liquidation value because they believe they can achieve impressive gains from their investments after the market has reasse...

Other stocks mentioned: CGA, UTSI
Business Wire - 3 months ago

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine disease...

Business Wire - 4 months ago

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Participate in September Investor Conferences

Business Wire - 5 months ago

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

Business Wire - 5 months ago

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Zacks Investment Research - 7 months ago

Investors need to pay close attention to Millendo (MLND) stock based on the movements in the options market lately.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Millendo Therapeutics.

Seeking Alpha - 1 year ago

Millendo Therapeutics: A Forgotten Biotech With Strong Potential

Benzinga - 1 year ago

Millendo Therapeutics Inc’s (NASDAQ: MLND) lead asset livoletide is in a registrational study (ZEPHYR) for the treatment of PraderWilli Syndrome (PWS), which is an unmet need, according to Wed...

24/7 Wall Street - 1 year ago

It’s not that unusual in the world of biotech and emerging medtech to run across companies that have previously never been heard of or covered.

About MLND

Millendo Therapeutics, a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

Industry
Biotechnology
CEO
Julia Owens
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
MLND
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for MLND stock is "Hold." The 12-month stock price forecast is 2.00, which is an increase of 3.09% from the latest price.

Price Target
$2.00
(3.09% upside)
Analyst Consensus: Hold